NCT00028496 - Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

November 30, 2005

Conditions

Adenocarcinoma of the ColonAdenocarcinoma of the GallbladderAdenocarcinoma of the PancreasAdenocarcinoma of the RectumAdult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerCholangiocarcinoma of the GallbladderDiffuse Adenocarcinoma of the StomachIntestinal Adenocarcinoma of the StomachMale Breast CancerMixed Adenocarcinoma of the StomachOvarian Endometrioid AdenocarcinomaPaget Disease of the Breast With Intraductal CarcinomaPaget Disease of the Breast With Invasive Ductal CarcinomaRecurrent Adult Primary Liver CancerRecurrent Breast CancerRecurrent Colon CancerRecurrent Gallbladder CancerRecurrent Gastric CancerRecurrent Malignant Testicular Germ Cell TumorRecurrent Pancreatic CancerRecurrent Rectal CancerRecurrent Salivary Gland CancerSalivary Gland AdenocarcinomaStage II Malignant Testicular Germ Cell TumorStage II Pancreatic CancerStage III Colon CancerStage III Gastric CancerStage III Malignant Testicular Germ Cell TumorStage III Pancreatic CancerStage III Rectal CancerStage III Salivary Gland CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IV Breast CancerStage IV Colon CancerStage IV Gastric CancerStage IV Pancreatic CancerStage IV Rectal CancerStage IV Salivary Gland CancerThyroid Gland Medullary CarcinomaUnresectable Gallbladder Cancer

Interventions

BIOLOGICAL

recombinant fowlpox-CEA(6D)/TRICOM vaccine

Given intradermally

BIOLOGICAL

sargramostim

Given subcutaneously

BIOLOGICAL

recombinant fowlpox GM-CSF vaccine adjuvant

Given intradermally

Trial Locations (1)

19111-2497

Fox Chase Cancer Center, Philadelphia

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH